Last year, the single most common reason a Korean was admitted to a hospital stopped being birth.

It became cataract surgery.

According to the Health Insurance Review and Assessment Service, 337,270 people were admitted for senile cataract in 2025. That was up 5.4 percent on the previous year. Live births, the category that held the top spot a decade ago, slipped to roughly 210,000. In 2014, by contrast, cataract sat in third place with 251,008 admissions.

That reversal is the cleanest one-line summary of Korean demographics you will ever read. However, it is also something less obvious. It is the demand engine behind Korea eye tech, an industry foreign investors almost never think about when they think about Korea.

They probably should. Korean companies now sell blindness drugs across Europe. Moreover, they hold FDA approvals for the biggest eye drug on earth, and they build AI that reads heart risk from a photograph of your retina.

Why the Korean Ophthalmology Industry Had a Head Start

Every industry needs a domestic market cruel enough to sharpen it. Korea’s eyes provided one.

The numbers are genuinely extreme. In its 2025 Eye Day fact sheet, the Korean Ophthalmological Society noted that roughly 30 percent of the world is nearsighted today. By 2050, the society expects that share to reach half of humanity. Prevalence across East Asia, meanwhile, already runs at 80 to 90 percent.

Korea sits at the top of that band. The Korea Herald, citing research published in the British Journal of Ophthalmology, reported that seven in ten Korean children are short-sighted.

School screening data tells the same story in a steeper line. Among first-graders, about 31 percent show impaired vision. By the first year of high school, the figure reaches roughly 75 percent. Furthermore, adult myopia has climbed from around 35 percent in 2008 to 53 percent by 2020 among Koreans over 40. Nationwide surveys put myopia among children and adolescents at 65.4 percent, with high myopia at 6.9 percent.

High myopia is the part clinicians worry about. It raises lifetime risk of retinal detachment, glaucoma, and myopic maculopathy. In other words, Korea has been manufacturing future retinal patients for thirty years.

The Myopia Control Market Korea Built by Accident

Consequently, an entire clinical infrastructure grew up around slowing that progression.

Korean parents encounter three main options, usually before their child turns ten. First come orthokeratology lenses, worn overnight to reshape the cornea, known locally as dream lenses. Second are myopia-control spectacle lenses with defocus microstructures. Third, and newest, are low-dose atropine eye drops from domestic manufacturers such as Taejoon and Unimed.

Notably, that third option sits in a regulatory grey zone. No atropine product in Korea carries a formal licence for myopia control itself, so prescribing happens off-label at the doctor’s discretion. Nevertheless, demand keeps rising, and the Korean Myopia Society published a full management consensus statement in 2025 to standardise practice.

The economics are worth noticing. None of these treatments are covered by national insurance. Therefore, families pay out of pocket, often for five or six years running, in a country where private education spending already normalises long-horizon child investment. That is the first thing to understand about the Korean ophthalmology industry. It scaled on a population that visits the eye doctor early, often, and at full price.

The Aging Half of the Equation

Then that same population got old, faster than any developed country in history.

Cataract surgery is now routine here, almost banal. Nevertheless, the money involved is not. Inpatient cataract care alone consumed roughly 614 billion won of national health insurance spending in 2024, close to $440 million. That figure excludes the premium lenses patients buy privately.

Those premium lenses are where the domestic market gets messy. Multifocal intraocular lenses, marketed as a way to escape reading glasses forever, are not covered by national insurance. Moreover, private indemnity insurers spent years fighting claims for them, arguing that the multifocal upgrade is vision correction rather than treatment. Courts have gone both ways. Policies tightened after 2016, and clinics still advertise aggressively into the gap.

For the wider Korea silver economy, that pattern is familiar. Aging creates volume, volume creates a premium tier, and the premium tier arrives before the rules do.

Korea Eye Tech’s Biggest Bet Is a Drug You Have Never Heard Of

Now move up the value chain, because this is where the story turns global.

Aflibercept — sold as Eylea by Regeneron and Bayer — treats wet age-related macular degeneration and diabetic macular edema. It is injected directly into the eye, roughly every eight weeks, for years on end. In short, it stands between millions of people and blindness. Korean media put its annual global sales at around 12 trillion won, close to $9 billion.

Then its patents began expiring. Consequently, four Korean companies went after it at once.

Company	Product	Status
Samsung Bioepis	Opuviz	FDA approved May 2024; launched across Europe in 2026
Celltrion	Eydenzelt	FDA approved October 2025; EU approval February 2025
Samchundang Pharm	Aflibercept biosimilar	Launched in Europe from late 2025
Alteogen	Eyluxvi	EC marketing authorisation granted in 2025

Read that table again. In a therapeutic area historically owned by American, Swiss, and German firms, the challenger field is now mostly Korean.

Samsung Bioepis took the direct route in Europe. It launched Opuviz across the region after settling with Regeneron and Bayer in January 2026, and the same product sells at home under the name Afilivu. Celltrion, meanwhile, chose a harder road. The company sells directly rather than through partners, which costs more but keeps the margin. Its Eydenzelt approval from the FDA in October 2025 was its first ophthalmology biologic cleared in the United States.

The Patent Wall Investors Keep Missing

Here is the part that rarely makes headlines, and it matters more than the approvals do.

Approval is not access. Regeneron sued nearly everyone, and American courts kept most aflibercept biosimilars off the shelf. Preliminary injunctions blocked US launches by both Samsung Bioepis and Celltrion. For a long stretch, Amgen’s Pavblu was the only aflibercept biosimilar actually selling in the country.

Settlements have since unlocked the calendar. Under its agreement with Regeneron, Celltrion may launch Eydenzelt in the US on the last day of 2026. Samsung Bioepis chose a different door into the same market. It handed American commercialisation to Harrow, a Nashville-based ophthalmic specialist, which launched Byooviz in July 2026 and holds exclusive US rights to Opuviz as well.

Therefore, the honest read on Korea eye tech in mid-2026 is straightforward. Europe is revenue today. America is a dated option, not a running business. Anyone modelling these companies on approval headlines alone is modelling the wrong thing.

The Risk Nobody Prices In

Still, a biosimilar strategy has one structural weakness. Originators rarely stand still.

Regeneron responded to patent expiry the way pharmaceutical incumbents usually do. It launched a higher-dose version of aflibercept, protected by fresh intellectual property, and pushed prescribers toward it. Meanwhile, Roche has been expanding Vabysmo, a bispecific antibody that promises longer intervals between injections. Both moves pull the most profitable patients away from the molecule Korean firms just spent a decade copying.

Retinal specialists, however, do not switch quickly. Injection schedules run for years, and payers in Europe apply heavy pressure toward cheaper options. Consequently, the Korean bet is less about winning new prescriptions than about capturing the enormous installed base of existing ones at a lower price.

Pricing is the other pressure point. Six aflibercept biosimilars have cleared the FDA, and European tenders reward whoever discounts hardest. Therefore, margin compression is not a risk in this category. It is the business model.

The Retina Became a Diagnostic Window

Drugs are one layer. The stranger, more distinctly Korean layer is diagnostics.

The eye is the only place in the body where a clinician can see blood vessels directly, without cutting anything open. Seoul-based Mediwhale built a company on that fact. Its software, Dr. Noon, analyses a single retinal photograph and estimates cardiovascular risk. No radiation, no blood draw, results in minutes.

The company reports accuracy comparable to cardiac CT, supported by peer-reviewed work including a pivotal study in JAMIA. Furthermore, adoption looks real rather than pilot-stage, with deployment across roughly 170 institutions in Korea and abroad. Founded in 2016, Mediwhale raised 20 billion won in a Series C round led by Premier Partners in 2026, bringing total funding to 51.2 billion won. The same platform also screens for glaucoma, cataract, and diabetic retinopathy from that one image.

Two 2026 milestones matter for foreign readers. First, Dr. Noon received CE MDR certification in May. That opens all 27 EU markets and, unusually, recognises risk prediction rather than diagnosis alone. Second, the company is working through the FDA’s De Novo pathway while preparing a public listing.

The strategic logic deserves a pause. Suppose retinal imaging becomes a routine screen for heart and kidney disease. The fundus camera then migrates out of the eye clinic and into primary care. Consequently, the addressable market stops being ophthalmology and becomes chronic disease management. That is a far larger number, and it explains why investors in Korean medical AI keep circling this category.

Hardware partnerships follow the same logic. Mediwhale has tied its software to fundus cameras already cleared for American clinics, which removes one procurement obstacle before regulators clear the second.

The Consumer Layer Nobody Files Under Healthcare

Meanwhile, at the opposite end of the seriousness spectrum, Korea exports eyes as fashion.

Cosmetic colored contact lenses are a Korean specialty in the same way cushion foundation is. Industry estimates put the domestic cosmetic lens market at roughly 720 billion won in 2024. That is more than half of the entire 1.3 trillion won contact lens market, with 800 billion won plausible in 2026. In other words, lenses worn for looks now outsell lenses worn for sight.

The brands travel well. OLENS, run by Starvision, built its reputation on Blackpink collaborations and sells through 200-plus Don Quijote stores in Japan, where it has reported topping the chain’s colored lens sales. Hapa Kristin ships worldwide with an IVE ambassador attached. Lens Me, i-DOL, and Clalen fill out a category that behaves less like optical retail and more like K-beauty.

Nevertheless, a caution belongs here. Cosmetic lenses are regulated medical devices in Korea. Unapproved lenses sold through social commerce have driven dry eye and corneal infection cases, so buy from a licensed optician rather than an Instagram seller.

What the Korea Eye Care Market Looks Like From the Clinic

Step back down to street level and the picture gets less triumphant.

Korea treated 2.01 million foreign patients in 2025, and dermatology absorbed 62.9 percent of them. Ophthalmology appears nowhere near the top of that ranking. So while Korea’s medical tourism boom exports skin treatments by the million, eye care remains overwhelmingly a domestic business serving domestic patients.

Vision correction surgery illustrates that dynamic well. LASIK, LASEK, SMILE, and implantable collamer lenses are widely available, technically excellent, and priced far below American equivalents. However, they are also advertised like consumer electronics, with event pricing, package upgrades, and influencer promotion. Clinical quality is generally high. Marketing discipline is not.

The device layer tells a similar story. Korean surgeons operate on femtosecond and excimer platforms built mostly by German, Swiss, and American manufacturers. Korea, in other words, is a heavy buyer of imported hardware and a heavy exporter of software and biologics. That asymmetry shapes where the domestic margin actually sits.

Screening habits complicate the picture further. Korea catches myopia early because schools test for it, yet glaucoma often goes undetected until damage is permanent. The disease is painless in its early stages, and national screening does not include a routine optic nerve exam for younger adults. Consequently, the country that photographs retinas for cardiovascular research still misses a preventable cause of blindness in ordinary check-ups. Ophthalmologists have campaigned on exactly this point for years.

There is also a measurement problem. Because so much of Korean eye care sits in the non-reimbursed private tier, no reliable won-denominated figure exists for the total size of the Korea eye care market. Anyone quoting one is estimating. That gap recurs throughout the Korean healthcare system, where universal coverage sits beside a large and lightly measured private layer.

Three Layers of Korea Eye Tech for Investors

For anyone building a thesis here, the sector splits into three tiers with very different risk profiles.

Biologics. Samsung Bioepis, Celltrion, Samchundang, and Alteogen compete in a market with real volume and brutal pricing. Furthermore, this is a manufacturing and litigation game rather than a discovery game. Watch settlement dates, European tender outcomes, and prefilled syringe approvals, since presentation format drives clinic adoption more than outsiders expect.

Diagnostics and AI. Mediwhale is the clearest name, though the thesis runs broader than one company. Retinal screening converts a cheap image into a chronic-disease risk score. Consequently, the winners will be whoever secures reimbursement codes first, not whoever publishes the best accuracy figure.

Consumer optics. Colored lenses, myopia-control products, and eyewear ride cultural export rather than clinical evidence. Margins look good, moats stay thin, and celebrity contracts function as the real competitive advantage.

Each layer carries a distinct failure mode. Biologics can be blocked by courts. Diagnostics can be stranded without reimbursement. Consumer optics can lose a brand ambassador and half a season with her.

A Practical Guide to Eye Care in Korea

If you live here, the industry above is also just your local clinic. A few things are worth knowing.

Eye exams are cheap and fast. A basic refraction and pressure check at a neighbourhood ophthalmology clinic typically costs a few tens of thousands of won. Walk-ins are normal. Optical shops also perform free refractions, though those are retail measurements rather than medical exams.

Ask what the retinal photo is for. Fundus imaging increasingly comes bundled into check-ups, sometimes with an AI risk report attached. It is generally not covered by national insurance, so confirm the price before agreeing.

Get vision correction quotes in writing. Ask which laser platform the clinic uses, what the total includes, and what follow-up visits cost. Aggressive event pricing at an unfamiliar clinic deserves the same suspicion it would anywhere else.

Treat the cataract lens as a separate decision. The surgery itself is insured. The premium multifocal lens usually is not, and pricing for the identical lens can differ by millions of won between clinics.

Bring a prescription for lenses. Korean opticians sell colored lenses readily, but power, base curve, and material still matter. Silicone hydrogel costs more and breathes better, which matters if you wear lenses daily.

Learn two words. An-gwa means ophthalmology clinic, and an-gyeong-won means optical shop. They are different businesses, and only the first one has a doctor in it.

What Korea Sees Next

Korea did not set out to build an eye industry. Instead, it produced the world’s most nearsighted generation, then aged faster than anyone else, and the industry assembled itself around those two facts.

The export phase is the interesting part. Korean firms are no longer selling only to Korean eyes. They supply European hospitals with blindness drugs, court American primary care with retinal AI, and ship cosmetic lenses to teenagers in São Paulo. Furthermore, all three run on the same underlying asset: two decades of clinical volume in a small, dense, heavily screened population.

That is the same playbook K-beauty and K-content used. Master an unreasonably demanding home market, then treat success there as certification everywhere else.

The difference this time is that almost nobody outside Korea has noticed yet. For investors, the quiet is the opportunity. For everyone else, it is a reasonable excuse to finally book that eye exam.